Highly organized nanostructures for brain drug delivery - new hope or just a fad?

CNS and Neurological Disorders - Drug Targets

Volumn 12, Issue 8, 2013, Pages 1271-1285

  Labuzek, K ^a   Gorki, K ^a   Jaroszek, H ^b   Jarzabek, K ^a   Gabryel, B ^a   Okopien, B ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b Biodegradable Plastics Research Group   (Poland)

Author keywords

Blood brain barrier; Brain drug delivery; Drug delivery systems; Nanocarriers; Nanoparticles; Nanotechnology

Indexed keywords

ALPHA SYNUCLEIN; CARBON NANOTUBE; CETUXIMAB; DAUNORUBICIN; DENDRIMER; DOCETAXEL; DOXORUBICIN; DRUG CARRIER; ENBUCRILATE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; FLUOROURACIL; FOLATE RECEPTOR; FULLERENE DERIVATIVE; INSULIN RECEPTOR; LACTOFERRIN; LIPOSOME; LOW DENSITY LIPOPROTEIN RECEPTOR; MACROGOL; METHYLPREDNISOLONE; NANOMATERIAL; NANOPARTICLE; NANOTUBE; NAVELBINE; OLIGONUCLEOTIDE; PACLITAXEL; POLYSORBATE 80; TRANSFERRIN RECEPTOR; ZIDOVUDINE; DRUG;

BLOOD BRAIN BARRIER; CLINICAL TRIAL (TOPIC); DEGENERATIVE DISEASE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RELEASE; DRUG SELECTIVITY; DRUG SOLUBILITY; ENCAPSULATION; GLIOMA; HUMAN; HYDROGEL; HYDROPHOBICITY; MICELLE; NANOTECHNOLOGY; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NONHUMAN; OXIDATIVE STRESS; REVIEW; ANIMAL; BRAIN; CHEMISTRY; DRUG EFFECTS; METABOLISM; PATHOLOGY; PROCEDURES; TRENDS;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NANOSTRUCTURES; PHARMACEUTICAL PREPARATIONS;

EID: 84891697234     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: None     Document Type: Review

References (160)

1. Dua, T.; Garrido-Cumbrera, M.; Mathers, C.; Saxena, S. In: Neurological disorders: public health challenges; WHO, Ed.; World Health Organization Press: Geneva, 2006; pp. 27-39.
2. Crone, C.; Olesen, S.P. Electrical resistance of brain microvascular endothelium. Brain Res., 1982, 241 (1), 49-55.
3. Hawkins, B.T.; Davis, T.P. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev., 2005, 57 (2), 173-185.
4. Pardridge, W.M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx., 2005, 2 (1), 3-14.
5. Engelhardt; B.; Sorokin, L. The blood-brain and the bloodcerebrospinal fluid barriers: function and dysfunction. Semin. Immunopathol., 2009, 31 (4), 497-511.
6. Deng, C.; Jiang, Y.J.; Cheng, R.; Meng, F.H.; Zhong, Z.Y. Biodegradable polymeric micelles for targeted and controlled anticancer drug delivery: promises, progress and prospects. Nano Today, 2012, 7 (5), 467-480.
7. Bae, Y.; Kataoka, K. Intelligent polymeric micelles from functional poly (ethylene glycol)-poly (amino acid) block copolymers. Adv. Drug Deliv. Rev., 2009, 61 (10), 768-784.
8. Misra, A.; Ganesh, S.; Shahiwala, A.; Shah, S.P. Drug delivery to the central nervous system: a review. J. Pharm. Sci., 2003, 6 (2), 252-273.
9. Iyer, A.K.; Khaled, G.; Fang, J.; Maeda, H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today, 2006, 11 (17-18), 812-818.
10. Béduneau, A.; Saulnier, P.; Benoit, J.P. Active targeting of brain tumors using nanocarriers. Biomaterials, 2007, 28 (33), 4947-4967.
11. Wong, H.L.; Wu, X.Y.; Bendayan, R. Nanotechnological advances for the delivery of CNS therapeutics. Adv. Drug Deliv. Rev., 2012, 64 (7), 686-700.
12. Masserini, M. Nanoparticles for Brain Drug Delivery. ISRN Biochemistry, 2013, 2013, 238428.
13. Chen, Y.; Liu, L. Modern methods for delivery of drugs across the blood-brain barrier. Adv. Drug Deliv. Rev., 2012, 64 (7), 640-665.
14. Alam, M.I.; Beg, S.; Samad, A.; Baboota, S.; Kohli, K.; Ali, J.; Ahuja, A.; Akbar, M. Strategy for effective brain drug delivery. Eur. J. Pharm. Sci., 2010, 40 (5), 385-403.
15. Krol, S. Challenges in drug delivery to the brain: nature is against us. J. Control. Release, 2012, 164 (2), 145-155.
16. De Rosa, G.; Salzano, G.; Caraglia, M.; Abbruzzese, A. Nanotechnologies: a strategy to overcome blood-brain barrier. Curr. Drug Metab., 2012, 13 (1), 61-69.
17. Sadekar, S.; Ghandehari, H. Transepithelial transport and toxicity of PAMAM dendrimers: implications for oral drug delivery. Adv. Drug Deliv. Rev., 2012, 64 (6), 571-588.
18. Shah, S.; Liu, Y.; Hu, W.; Gao, J. Modeling particle shapedependent dynamics in nanomedicine. J. Nanosci. Nanotechnol., 2011, 11 (2), 919-928.
19. Uhrich, K.E.; Cannizzaro, S.M.; Langer, R.S.; Shakesheff, K.M. Polymeric systems for controlled drug release. Chem. Rev., 1999, 99 (11), 3181-3198.
20. Kost, J.; Langer, R. Responsive polymeric delivery systems. Adv. Drug. Deliv. Rev., 2001, 46 (1-3), 125-148.
21. Colson, Y.L.; Grinstaff, M.W. Biologically responsive polymeric nanoparticles for drug delivery. Adv. Mater., 2012, 24 (28), 3878-3886.
22. Adams, M.L.; Lavasanifar, A.; Kwon, G.S. Amphiphilic block copolymers for drug delivery. J. Pharm. Sci., 2003, 92 (7), 1343-1355.
23. Batrakova, E.V.; Kabanov, A.V. Pluronic Block Copolymers. J. Control. Release, 2008, 130 (2), 98-106.
24. Batrakova, E.V.; Han, H.Y.; Miller, D.W.; Kabanov, A.V. Effects of pluronic P85 unimers and micelles on drug permeability in polarized BBMEC and Caco-2 cells. Pharm. Res., 1998, 15 (10), 1525-1532.
25. Matsumura, Y. Poly (amino acid) micelle nanocarriers in preclinical and clinical studies. Adv. Drug Deliv. Rev., 2008, 60 (8), 899-914.
26. Osada, K.; Christie, R.J.; Kataoka, K. Polymeric micelles from poly (ethylene glycol)-poly (amino acid) block copolymer for drug and gene delivery. J.R. Soc. Interface, 2009, 6 (Suppl 3), S325-S339.
27. Wei, Z.; Yuan, S.; Hau, J.; Fang, X. Mechanism of inhibition of Pglycoprotein mediated Efflux by Pluronic P123/F127 block copolymers: Relationship between copolymer concentration and inhibitory activity. Eur. J. Pharm. Biopharm., 2013, 83 (2), 266-274.
28. Kabanov, A.V.; Chekhonin, V.P.; Alakhov, V.Y.; Batrakova, E.V.; Lebedev, A.S.; Melik-Nubarov, N.S.; Arzhakov, S.A.; Levashov, A.V.; Morozov, G.V.; Severin, E.S.; Kabanov, V.A. The neuroleptic activity of haloperidol increases after its solubilization in surfactant micelles. Micelles as microcontainers for drug targeting. FEBS Lett., 1989, 258 (2), 343-345.
29. Kabanov, A.V.; Batrakova, E.V.; Melik-Nubarov, N.S.; Fedoseev, N.A.; Dorodnich, T.Y.; Alakhov, V.Y.; Chekhonin, V.P.; Nazarova, I.R.; Kabanov, V.A. A new class of drug carriers: micelles of poly (oxyethylene)-poly (oxypropylene) block copolymers as microcontainers for drug targeting from blood in brain. J. Control. Release, 1992, 22 (2), 141-157.
30. Cambon, A.; Rey-Rico, A.; Barbosa, S.; Soltero, J.F.; Yeates, S.G.; Brea, J.; Loza, M.I.; Alvarez-Lorenzo, C.; Concheiro, A.; Taboada, P.; Mosquera, V. Poly (styrene oxide)-poly (ethylene oxide) block copolymers: From "classical" chemotherapeutic nanocarriers to active cell-response inducters. J. Control. Release, 2013, 167 (1), 68-75.
31. Qian, Y.; Zha, Y.; Feng, B.; Pang, Z.; Zhang, B.; Sun, X.; Ren, J.; Zhang, C.; Shao, X.; Zhang, Q.; Jiang, X. PEGylated poly (2-(dimethylamino) ethyl methacrylate) /DNA polyplex micelles decorated with phage-displayed TGN peptide for brain-targeted gene delivery. Biomaterials, 2013, 34 (8), 2117-2129.
32. Chiappetta, D.A.; Hocht, C.; Opezzo, J.A.; Sosnik, A. Intranasal administration of antiretroviral-loaded micelles for anatomical targeting to the brain in HIV. Nanomedicine (Lond.), 2013, 8 (2), 223-237.
33. Lavasanifar, A.; Samuel, J.; Kwon, G.S. Micelles of poly (ethylene oxide)-block-poly (N-alkyl stearate L-aspartamide), synthetic analogues of lipoproteins for drug delivery. J. Biomed. Mater. Res., 2000, 52 (4), 831-835.
34. Shao, K.; Wu, J.; Chen, Z.; Huang, S.; Li, J.; Ye, L.; Lou, J.; Zhu, L.; Jiang, C. A brain-vectored angiopep-2 based polymeric micelles for the treatment of intracranial fungal infection. Biomaterials, 2012, 33 (28), 6898-6907.
35. Oh, J.K.; Drumright, R.; Siegwart, D.J.; Matyjaszewski, K. The development of microgels/nanogels for drug delivery applications. Prog. Polym. Sci., 2008, 33, 448-477.
36. Vinogradov, S.V.; Batrakova, E.V.; Kabanov, A.V. Nanogels for Oligonucleotide Delivery to the Brain. Bioconjug. Chem., 2004, 15 (1), 50-60.
37. Vinogradov, S.V. Polymeric nanogel formulations of nucleoside analogs. Expert Opin. Drug. Deliv., 2007, 4 (1), 5-17.
38. Vinogradov, S.V. Nanogels in the race for drug delivery. Nanomedicine (Lond.), 2010, 5 (2), 165-168.
39. Vinogradov, S.V.; Batrakova, E.; Li, S.; Kabanov, A.V. Polyion complex micelles with protein-modified corona for receptormediated delivery of oligonucleotides into cells. Bioconjug. Chem., 1999, 10 (5), 851-860.
40. Soni, S.; Babbar, A.K.; Sharma, R.K.; Maitra, A. Delivery of hydrophobised 5-fluorouracil derivative to brain tissue through intravenous route using surface modified nanogels. J. Drug Target., 2007, 14 (2), 87-95.
41. Tian, X.H.; Lin, X.N.; Wei, F.; Feng, W.; Huang, Z.C.; Wang, P.; Ren, L.; Diao, Y. Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles. Int. J. Nanomedicine, 2011, 6, 445-452.
42. Gavegnano, C.; Schinazi, R.F. Antiretroviral therapy in macrophages: implication for HIV eradication. Antivir. Chem. Chemother., 2009, 20 (2), 63-78.
43. Vinogradov, S.V.; Poluektova, L.Y.; Makarov, E.; Gerson, T.; Senanayake, M.T. Nano-NRTIs: efficient inhibitors of HIV type-1 in macrophages with a reduced mitochondrial toxicity. Antivir. Chem. Chemother., 2010, 21 (1), 1-14.
44. Modi, G.; Pillay, V.; Choonara, Y.E. Advances in the treatment of neurodegenerative disorders employing nanotechnology. Ann. N.Y. Acad. Sci., 2010, 1184, 154-172.
45. Aulenta, F.; Hayes, W.; Rannard, S. Dendrimers: a new class of nanoscopic containers and delivery devices. Europ. Polym. J., 2003, 39 (9), 1741-1771.
46. Beg, S.; Samad, A.; Alam, M.I.; Nazish, I. Dendrimers as novel systems for delivery of neuropharmaceuticals to the brain. CNS Neurol. Disord. Drug Targets, 2011, 10 (5), 576-588.
47. Ding, B.S.; Dziubla, T.; Shuvaev, V.V.; Muro, S.; Muzykantov, V.R. Advanced drug delivery systems that target the vascular endothelium. Mol. Interv., 2007, 6 (2), 98-112.
48. Najlah, M.; D'Emanuele, A. Crossing cellular barriers using dendrimer nanotechnologies. Curr. Opin. Pharmacol., 2007, 6 (5), 522-527.
49. Saovapakhiran, A.; D'Emanuele, A.; Attwood, D.; Penny, J. Surface modification of PAMAM dendrimers modulates the mechanism of cellular internalization. Bioconjug. Chem., 2009, 20 (4), 693-701.
50. Svenson, S.; Tomalia, D.A. Dendrimers in biomedical applicationsreflections on the field. Adv. Drug Deliv. Rev., 2005, 57 (15), 2106-2129.
51. Lee, C.C.; MacKay, J.A.; Fréchet, J.M.; Szoka, F.C. Designing dendrimers for biological applications. Nat. Biotechnol., 2005, 23 (12), 1517-1526.
52. Morgan, M.T.; Nakanishi, Y.; Kroll, D.J.; Griset, A.P.; Carnahan, M.A.; Wathier, M.; Oberlies, N.H.; Manikumar, G.; Wani, M.C.; Grinstaff, M.W. Dendrimer-encapsulated camptothecins: increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro. Cancer Res., 2007, 66 (24), 11913-11921.
53. Majoros, I.J.; Myc, A.; Thomas, T.; Mehta, C.B.; Baker, J.R. Jr. PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules, 2007, 7 (2), 572-579.
54. Wu, G.; Barth, R.F.; Yang, W.; Kawabata, S.; Zhang, L.; Green-Church, K. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMCC225) dendrimer bioconjugates. Mol. Cancer Ther., 2007, 5 (1), 52-59.
55. He, H.; Li, Y.; Jia, X.R.; Du, J.; Ying, X.; Lu, W.L.; Lou, J.N.; Wei, Y. PEGylated Poly (amidoamine) dendrimer-based dualtargeting carrier for treating brain tumors. Biomaterials, 2011, 32 (2), 478-487.
56. Dhanikula, R.S.; Argaw, A.; Bouchard, J.F.; Hildgen, P. Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability. Mol. Pharm., 2008, 5 (1), 105-116.
57. Medina, S.H.; El-Sayed, M.E. Dendrimers as carriers for delivery of chemotherapeutic agents. Chem. Rev., 2009, 109 (7), 3141-3157.
58. Gajbhiye, V.; Jain, N.K. The treatment of Glioblastoma Xenografts by surfactant conjugated dendritic nanoconjugates. Biomaterials, 2011, 32 (26), 6213-6225.
59. Patel, S.K.; Gajbhiye, V.; Jain, N.K. Synthesis, characterization and brain targeting potential of paclitaxel loaded thiamine-PPI nanoconjugates. J. Drug Target., 2012, 20 (10), 841-849.
60. Zhang, L.; Zhu, S.; Qian, L.; Pei, Y.; Qiu, Y.; Jiang, Y. RGDmodified PEG-PAMAM-DOX conjugates: in vitro and in vivo studies for glioma. Eur. J. Pharm. Biopharm., 2011, 79 (2), 232-240.
61. Li, Y.; He, H.; Jia, X.; Lu, W.L.; Lou, J.; Wei, Y. A dual-targeting nanocarrier based on poly (amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomaterials, 2012, 33 (15), 3899-3908.
62. Barrett, T.; Ravizzini, G.; Choyke, P.L.; Kobayashi, H. Dendrimers Application Related to Bioimaging. IEEE Eng. Med. Biol. Mag., 2009, 28 (1), 12-22.
63. Capala, J.; Barth, R.F.; Bendayan, M.; Lauzon, M.; Adams, D.M.; Soloway, A.H.; Fenstermaker, R.A.; Carlsson, J. Boronated epidermal growth factor as a potential targeting agent for boron neutron capture therapy of brain tumors. Bioconjug. Chem., 1996, 7 (1), 7-15.
64. Yang, W.; Barth, R.F.; Adams, D.M.; Soloway, A.H. Intratumoral delivery of boronated epidermal growth factor for neutron capture therapy of brain tumors. Cancer Res., 1997, 57 (19), 4333-4339.
65. Wu, G.; Yang, W.; Barth, R.F.; Kawabata, S.; Swindall, M.; Bandyopadhyaya, A.K.; Tjarks, W.; Khorsandi, B.; Blue, T.E.; Ferketich, A.K.; Yang, M.; Christoforidis, G.A.; Sferra, T.J.; Binns, P.J.; Riley, K.J.; Ciesielski, M.J.; Fenstermaker, R.A. Molecular targeting and treatment of an epidermal growth factor receptorpositive glioma using boronated cetuximab. Clin. Cancer Res., 2007, 13 (4), 1260-1268.
66. Dai, H.; Navath, R.S.; Balakrishnan, B.; Guru, B.R.; Mishra, M.K.; Romero, R.; Kannan, R.M.; Kannan, S. Intrinsic targeting of inflammatory cells in the brain by polyamidoamine dendrimers upon subarachnoid administration. Nanomedicine (Lond.), 2010, 5 (9), 1317-1329.
67. Kannan, S.; Dai, H.; Navath, R.S.; Balakrishnan, B.; Jyoti, A.; Janisse, J.; Romero, R.; Kannan, R.M. Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model. Sci. Transl. Med., 2012, 4 (130), 130-146.
68. Klajnert, B.; Cortijo-Arellano, M.; Cladera, J.; Bryszewska, M. Influence of dendrimer's structure on its activity against amyloid fibril formation. Biochem. Biophys. Res. Commun., 2007, 345 (1), 21-28.
69. Supattapone, S.; Nguyen, H.O.; Cohen, F.E.; Prusiner, S.B.; Scott, M.R. Elimination of prions by branched polyamines and implications for therapeutics. Proc. Natl. Acad. Sci. U.S.A., 1999, 96 (25), 14529-14534.
70. Supattapone, S.; Wille, H.; Uyechi, L.; Safar, J.; Tremblay, P.; Szoka, F.C.; Cohen, F.E.; Prusiner, S.B.; Scott, M.R. Branched polyamines cure prion-infected neuroblastoma cells. J. Virol., 2001, 75 (7), 3453-3461.
71. Solassol, J.; Crozet, C.; Perrier, V.; Leclaire, J.; Béranger, F.; Caminade, A.M.; Meunier, B.; Dormont, D.; Majoral, J.P.; Lehmann, S. Cationic phosphorus-containing dendrimers reduce prion replication both in cell culture and in mice infected with scrapie. J. Gen. Virol., 2004, 85 (Pt 6), 1791-1799.
72. McCarthy, J.M.; Franke, M.; Resenberger, U.K.; Waldron, S.; Simpson, J.C.; Tatzelt, J.; Appelhans, D.; Rogers, M.S. Anti-Prion Drug mPPIg5 Inhibits PrP (C) Conversion to PrP (Sc). PLoS One, 2013, 8 (1), e55282.
73. Lim, Y.B.; Mays, C.E.; Kim, Y.; Titlow, W.B.; Ryou, C. The inhibition of prions through blocking prion conversion by permanently charged branched polyamines of low cytotoxicity. Biomaterials, 2010, 31 (8), 2025-2033.
74. Neelov, I.M.; Janaszewska, A.; Klajnert, B.; Bryszewska, M.; Makova, N.Z.; Hicks, D.; Pearson, H.A.; Vlasov, G.P.; Ilyash, M.Y.; Vasilev, D.S.; Dubrovskaya, N.M.; Tumanova, N.L.; Zhuravin, I.A.; Turner, A.J.; Nalivaeva, N.N. Molecular Properties of Lysine Dendrimers and their Interactions with Aβ-Peptides and Neuronal Cells. Curr. Med. Chem., 2013, 20 (1), 134-143.
75. Klajnert, B.; Wasiak, T.; Ionov, M.; Fernandez-Villamarin, M.; Sousa-Herves, A.; Correa, J.; Riguera, R.; Fernandez-Megia, E. Dendrimers reduce toxicity of Aβ 1-28 peptide during aggregation and accelerate fibril formation. Nanomedicine, 2012, 8 (8), 1372-1378.
76. Patel D.A.; Henry, J.E.; Good, T.A. Attenuation of beta-amyloidinduced toxicity by sialic-acid-conjugated dendrimers: role of sialic acid attachment. Brain Res., 2007, 1161, 95-105.
77. Wasiak, T.; Ionov, M.; Nieznanski, K.; Nieznanska, H.; Klementieva, O.; Granell, M.; Cladera, J.; Majoral, J.P.; Caminade, A.M.; Klajnert, B. Phosphorus dendrimers affect Alzheimer's (Aβ1-28) peptide and MAP-Tau protein aggregation. Mol. Pharm., 2012, 9 (3), 458-469.
78. Klementieva, O.; Benseny-Cases, N.; Gella, A.; Appelhans D.; Voit, B.; Cladera, J. Dense shell glycodendrimers as potential nontoxic anti-amyloidogenic agents in Alzheimer's disease. Amyloid-dendrimer aggregates morphology and cell toxicity. Biomacromolecules, 2011, 12 (11), 3903-3909.
79. Rekas, A.; Lo, V.; Gadd, G.E.; Cappai, R.; Yun, S.I. PAMAM dendrimers as potential agents against fibrillation of alphasynuclein, a Parkinson's disease-related protein. Macromol. Biosci., 2009, 9 (3), 230-238.
80. Milowska, K.; Grochowina, J.; Katir, N.; El Kadib, A.; Majoral, J.P.; Bryszewska, M.; Gabryelak, T. Viologen-Phosphorus Dendrimers Inhibit α-Synuclein Fibrillation. Mol. Pharm., 2013, 10 (3), 1131-1137.
81. Huang, R.; Han, L.; Li, J.; Ren, F.; Ke, W.; Jiang, C.; Pei, Y. Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles. J. Gene Med., 2009, 11 (9), 754-763.
82. Dugan, L.L.; Turetsky, D.M.; Du, C; Lobner, D.; Wheeler, M.; Almli, C.R.; Shen, C.K.; Luh, T.Y.; Choi, D.W.; Lin, T.S. Carboxyfullerenes as neuroprotective agents. Proc. Natl. Acad. Sci. USA, 1997, 94 (17), 9434-9439.
83. Ali, S.S.; Hardt, J.I.; Quick, K.L.; Kim-Han, J.S.; Erlanger, B.F.; Huang, T.T.; Epstein, C.J.; Dugan, L.L. A biologically effective fullerene (C60) derivative with superoxide dismutase mimetic properties. Free Radic. Biol. Med., 2004, 37 (8), 1191-1202.
84. Ali, S.S.; Hardt, J.I.; Dugan, L.L. SOD activity of carboxyfullerenes predicts their neuroprotective efficacy: a structure-activity study. Nanomedicine, 2008, 4 (4), 283-294.
85. Jin, H.; Chen, W.Q.; Tang, X.W.; Chiang, L.Y.; Yang, C.Y.; Schloss, J.V.; Wu, J.Y. Polyhydroxylated C (60), fullerenols, as glutamate receptor antagonists and neuroprotective agents. J. Neurosci. Res., 2000, 62 (4), 600-607.
86. Basso, A.S.; Frenkel, D.; Quintana, F.J.; Costa-Pinto, F.A.; Petrovic-Stojkovic, S.; Puckett, L.; Monsonego, A.; Bar-Shir, A.; Engel, Y.; Gozin, M.; Weiner, H.L. Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J. Clin. Invest., 2008, 118 (4), 1532-1543.
87. Giust, D.; León, D.; Ballesteros-Yañez, I.; Da Ros, T.; Albasanz, J.L.; Martín, M. Modulation of adenosine receptors by [60]fullerene hydrosoluble derivative in sk-N-mc cells. ACS Chem. Neurosci., 2011, 2 (7), 363-369.
88. Lao, F.; Chen, L.; Li, W.; Ge, C.; Qu, Y.; Sun, Q.; Zhao, Y.; Han, D.; Chen, C. Fullerene nanoparticles selectively enter oxidationdamaged cerebral microvessel endothelial cells and inhibit JNKrelated apoptosis. ACS Nano., 2009, 3 (11), 3358-3368.
89. Tsao, N.; Kanakamma, P.P.; Luh, T.Y.; Chou, C.K.; Lei, H.Y. Inhibition of Escherichia coli-induced meningitis by carboxyfullerence. Antimicrob. Agents Chemother., 1999, 43 (9), 2273-227.
90. Huang, S.S.; Tsai, S.K.; Chih, C.L.; Chiang, L.Y.; Hsieh, H.M.; Teng, C.M.; Tsai, M.C. Neuroprotective effect of hexasulfobutylated C60 on rats subjected to focal cerebral ischemia. Free Radic. Biol. Med., 2001, 30 (6), 643-649.
91. Yang, D.Y.; Wang, M.F.; Chen, I.L.; Chan, Y.C.; Lee, M.S.; Cheng, F.C. Systemic administration of a water-soluble hexasulfonated C (60) (FC (4) S) reduces cerebral ischemia-induced infarct volume in gerbils. Neurosci. Lett., 2001, 311 (2), 121-124.
92. Behrens, M.M.; Ali, S.S.; Dao, D.N.; Lucero, J.; Shekhtman, G.; Quick, K.L.; Dugan, L.L. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science, 2007, 318 (5856), 1645-1647.
93. Tykhomyrov, A.A.; Nedzvetsky, V.S.; Klochkov, V.K.; Andrievsky, G.V. Nanostructures of hydrated C60 fullerene (C60HyFn) protect rat brain against alcohol impact and attenuate behavioral impairments of alcoholized animals. Toxicology, 2008, 246 (2-3), 158-165.
94. Makarova, E.G.; Gordon, R.Y.; Podolski, I.Y. Fullerene C60 prevents neurotoxicity induced by intrahippocampal microinjection of amyloid-beta peptide. J. Nanosci. Nanotechnol., 2012, 12 (1), 119-126.
95. Luo, X.; Matranga, C.; Tan, S.; Alba, N.; Cui, X.T. Carbon nanotube nanoreservior for controlled release of anti-inflammatory dexamethasone. Biomaterials, 2011, 32 (26), 6316-6323.
96. Kateb, B.; Van Handel, M.; Zhang, L.; Bronikowski, M.J.; Manohara, H.; Badie, B. Internalization of MWCNTs by microglia: possible application in immunotherapy of brain tumors. Neuroimage, 2007, 37 (Suppl 1), S9-S17.
97. Yang, Z.; Zhang, Y.; Yang, Y.; Sun, L.; Han, D.; Li, H.; Wang, C. Pharmacological and toxicological target organelles and safe use of single-walled carbon nanotubes as drug carriers in treating Alzheimer disease. Nanomedicine, 2010, 6 (3), 427-441.
98. VanHandel, M.; Alizadeh, D.; Zhang, L.; Kateb, B.; Bronikowski, M.; Manohara, H.; Badie, B. Selective uptake of multi-walled carbon nanotubes by tumor macrophages in a murine glioma model. J. Neuroimmunol., 2009, 208 (1-2), 3-9.
99. Zhao, D.; Alizadeh, D.; Zhang, L.; Liu, W.; Farrukh, O.; Manuel, E.; Diamond, D.J.; Badie, B. Carbon nanotubes enhance CpG uptake and potentiate antiglioma immunity. Clin. Cancer Res., 2011, 17 (4), 771-782.
100. Jia, G.; Wang, H.; Yan, L.; Wang, X.; Pei, R.; Yan, T.; Zhao, Y.; Guo, X. Cytotoxicity of Carbon Nanomaterials: Single-Wall Nanotube, Multi-Wall Nanotube, and Fullerene. Environ. Sci. Technol., 2005, 39 (5), 1378-1383.
101. Lam, C.W.; James, J.T.; McCluskey, R.; Arepalli, S.; Hunter, R.L. A review of carbon nanotube toxicity and assessment of potential occupational and environmental health risks. Crit. Rev. Toxicol., 2007, 36 (3), 189-217.
102. Kolosnjaj, J.; Szwarc, H.; Moussa, F. Toxicity studies of fullerenes and derivatives. Adv. Exp. Med. Biol., 2007, 620, 168-180.
103. Kolosnjaj, J.; Szwarc, H.; Moussa, F. Toxicity studies of carbon nanotubes. Adv. Exp. Med. Biol., 2007, 620, 181-204.
104. Soppimath, K.S.; Aminabhavi, T.M.; Kulkarni, A.R.; Rudzinski, W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release, 2001, 70 (1-2), 1-20.
105. Tamada, J.A.; Langer, R. Erosion kinetics of hydrolytically degradable polymers. Proc. Natl. Acad. Sci. USA, 1993, 90 (2), 552-556.
106. Olivier, J.C. Drug Transport to Brain with Targeted Nanoparticles. NeuroRx., 2005, 2 (1), 108-119.
107. Calvo, P.; Gouritin, B.; Chacun, H.; Desmaële, D.; D'Angelo, J.; Noel, J.P.; Georgin, D.; Fattal, E.; Andreux, J.P.; Couvreur, P. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res., 2001, 18 (8), 1157-1166.
108. Kreuter, J. Influence of the surface properties on nanoparticlemediated transport of drugs to the brain. J. Nanosci. Nanotechnol., 2004, 4 (5), 484-488.
109. Kreuter, J.; Ramge, P.; Petrov, V.; Hamm, S.; Gelperina, S.E.; Engelhardt, B.; Alyautdin, R.; von Briesen, H.; Begley, D.J. Direct evidence that polysorbate-80-coated poly (butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm. Res., 2003, 20 (3), 409-416.
110. Olivier, J.C.; Fenart, L.; Chauvet, R.; Pariat, C.; Cecchelli, R.; Couet, W. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm. Res., 1999, 16 (12), 1836-1842.
111. Steiniger, S.C.; Kreuter, J.; Khalansky, A.S.; Skidan, I.N.; Bobruskin, A.I.; Smirnova, Z.S.; Severin, S.E.; Uhl, R.; Kock, M.; Geiger, K.D.; Gelperina, S.E. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int. J. Cancer, 2004, 109 (5), 759-767.
112. Aliautdin, R.N.; Petrov, V.E.; Langer, K.; Berthold, A.; Kreuter, J.; Kharkevich, D.A. The delivery of loperamide to the brain by using polybutyl cyanoacrylate nanoparticles. Eksp. Klin. Farmakol., 1998, 61 (1), 17-20.
113. Alyaudtin, R.N.; Reichel, A.; Löbenberg, R.; Ramge, P.; Kreuter, J.; Begley, D.J. Interaction of poly (butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. J. Drug Target, 2001, 9 (3), 209-21.
114. Friese, A,. Seiller, E.; Quack, G.; Lorenz, B.; Kreuter, J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly (butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur. J. Pharm. Biopharm., 2000, 49 (2), 103-109.
115. Kuo, Y.C.; Chung, C.Y. Transcytosis of CRM197-grafted polybutylcyanoacrylate nanoparticles for delivering zidovudine across human brain-microvascular endothelial cells. Colloids Surf. B. Biointerfaces, 2012, 91, 242-249.
116. Lin, Y.; Pan, Y.; Shi, Y.; Huang, X.; Jia, N.; Jiang, J.Y. Delivery of large molecules via poly (butyl cyanoacrylate) nanoparticles into the injured rat brain. Nanotechnology, 2012, 23 (16), 165101.
117. Avgoustakis, K. Pegylated poly (lactide) and poly (lactide-coglycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Curr. Drug Deliv., 2004, 1 (4), 321-333.
118. Song, Q.; Wang, X.; Hu, Q.; Huang, M.; Yao, L.; Qi, H.; Qiu, Y.; Jiang, X.; Chen, J.; Chen, H.; Gao, X. Cellular internalization pathway and transcellular transport of pegylated polyester nanoparticles in Caco-2 cells. Int. J. Pharm., 2013, 445 (1-2), 58-68.
119. Guo, J.; Gao, X.; Su, L.; Xia, H.; Gu, G.; Pang, Z.; Jiang, X.; Yao, L.; Chen, J.; Chen, H. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials, 2011, 32 (31), 8010-8020.
120. Panyam, J.; Labhasetwar, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev., 2003, 55 (3), 329-347.
121. Liu, G.; Men, P.; Perry, G.; Smith, M.A. Nanoparticle and iron chelators as a potential novel Alzheimer therapy. Methods Mol. Biol., 2010, 610, 123-144.
122. Cherny, R.A.; Atwood, C.S.; Xilinas, M.E.; Gray, D.N.; Jones, W.D.; McLean, C.A.; Barnham, K.J.; Volitakis, I.; Fraser, F.W.; Kim, Y.; Huang, X.; Goldstein, L.E.; Moir, R.D.; Lim, J.T.; Beyreuther, K.; Zheng, H.; Tanzi, R.E.; Masters, C.L.; Bush, A. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron, 2001, 30 (3), 665-676.
123. Cui, Z.; Lockman, P.R.; Atwood, C.S.; Hsu, C.H.; Gupte, A.; Allen, D.D.; Mumper, R.J. Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. Eur. J. Pharm. Biopharm., 2005, 59 (2), 263-272.
124. Marsh, J.N.; Senpan, A.; Hu, G.; Scott, M.J.; Gaffney, P.J.; Wickline, S.A.; Lanza, G.M. Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis. Nanomedicine (Lond.), 2007, 2 (4), 533-543.
125. Reddy, M.K.; Labhasetwar, V. Nanoparticle-mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemia-reperfusion injury. FASEB J., 2009, 23 (5), 1384-1395.
126. Marushima, A.; Suzuki, K.; Nagasaki, Y.; Yoshitomi, T.; Toh, K.; Tsurushima, H.; Hirayama, A.; Matsumura, A. Newly synthesized radical-containing nanoparticles enhance neuroprotection after cerebral ischemia-reperfusion injury. Neurosurgery, 2011, 68 (5), 1418-1425.
127. Sharma, A.; Sharma, U.S. Liposomes in drug delivery: Progress and limitations. Int. J. Pharm., 1997, 154 (2), 123-140.
128. Allen, C.; Dos Santos, N.; Gallagher, R.; Chiu, G.N.; Shu, Y.; Li, W.M.; Johnstone, S.A.; Janoff, A.S.; Mayer, L.D.; Webb, M.S.; Bally, M.B. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly (ethylene glycol). Biosci. Rep., 2002, 22 (2), 225-250.
129. Szebeni, J. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents. Crit. Rev. Ther. Drug Carrier Syst., 2001, 18 (6), 567-606.
130. Gabizon, A.; Catane, R.; Uziely, B.; Kaufman, B.; Safra, T.; Cohen, R.; Martin, F.; Huang, A.; Barenholz, Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res., 1994, 54 (4), 987-992.
131. Huwyler, J.; Wu, D.; Pardridge, W.M. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. USA, 1996, 93 (24), 14164-14169.
132. Aoki, H.; Kakinuma, K.; Morita, K.; Kato, M.; Kato, M.; Uzuka, T.; Igor, G.; Takahashi, H.; Tanaka, R. Therapeutic efficacy of targeting chemotherapy using local hyperthermia and thermosensitive liposome: evaluation of drug distribution in a rat glioma model. Int. J. Hyperthermia, 2004, 20 (6), 595-605.
133. Schmidt, J.; Metselaar, J.M.; Wauben, M.H.; Toyka, K.V.; Storm, G.; Gold, R. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain, 2003, 126, 1895-1904.
134. Gaillard, P.J.; Appeldoorn, C.C.; Rip, J.; Dorland, R.; van der Pol, S.M.; Kooij, G.; de Vries, H.E.; Reijerkerk, A. Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation. J. Control. Release, 2012, 164 (3), 364-369.
135. Omori, N.; Maruyama, K.; Jin, G.; Li, F.; Wang, S.J.; Hamakawa, Y.; Sato, K.; Nagano, I.; Shoji, M.; Abe, K. Targeting of postischemic cerebral endothelium in rat by liposomes bearing polyethylene glycol-coupled transferrin. Neurol. Res., 2003, 25 (3), 275-279.
136. Zhao, H.; Bao, X.J.; Wang, R.Z.; Li, G.L.; Gao, J.; Ma, S.H.; Wei, J.J.; Feng, M.; Zhao, Y.J.; Ma, W.B.; Yang, Y.; Li, Y.N.; Kong, Y.G. Postacute ischemia vascular endothelial growth factor transfer by transferrin-targeted liposomes attenuates ischemic brain injury after experimental stroke in rats. Hum. Gene Ther., 2011, 22, 207-215.
137. Ishii, T.; Fukuta, T.; Agato, Y.; Oyama, D.; Yasuda, N.; Shimizu, K.; Kawaguchi, A.T.; Asai, T.; Oku, N. Nanoparticles accumulate in ischemic core and penumbra region even when cerebral perfusion is reduced. Biochem. Biophys. Res. Commun., 2013, 430, 1201-1205.
138. Shi, N.; Pardridge, W.M. Noninvasive gene targeting to the brain. Proc. Natl. Acad. Sci. USA, 2000, 97 (13), 7567-7572.
139. Shi, N.; Zhang, Y.; Zhu, C.; Boado, R.J.; Pardridge, W.M. Brain specific expression of an exogenous gene after i. v. administration. Proc. Natl. Acad. Sci. U.S.A., 2001, 98 (22), 12754-12759.
140. Zhang, Y.; Boado, R.J.; Pardridge, W.M.; Zhang, Y.; Boado, R.J.; Pardridge, W.M. Marked enhancement in gene expression by targeting the human insulin receptor. J. Gene Med., 2003, 5 (2), 157-163.
141. Pardridge, W.M. Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy. NeuroRx., 2005, 2 (1), 129-138.
142. Zhang, X.; Xie, Y.; Jin, Y.; Hou, X.; Ye, L.; Lou, J. The effect of RMP-7 and its derivative on transporting Evans blue liposomes into the brain. Drug Deliv., 2004, 11 (5), 301-309.
143. Mamot, C.; Drummond, D.C.; Greiser, U.; Hong, K.; Kirpotin, D.B.; Marks, J.D.; Park, J.W. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR-and EGFRvIII-overexpressing tumor cells. Cancer Res., 2003, 63 (12), 3154-3161.
144. Venishetty, V.K.; Komuravelli, R.; Kuncha, M.; Sistla, R.; Diwan, P.V. Increased brain uptake of docetaxel and ketoconazole loaded folate-grafted solid lipid nanoparticles. Nanomedicine, 2013, 9 (1), 111-121.
145. Kuo, Y.C.; Shih-Huang, C.Y. Solid lipid nanoparticles carrying chemotherapeutic drug across the blood-brain barrier through insulin receptor-mediated pathway. J. Drug Target., 2013, [Epub ahead of print].
146. Kuo, Y.C.; Ko, H.F. Targeting delivery of saquinavir to the brain using 83-14 monoclonal antibody-grafted solid lipid nanoparticles. Biomaterials, 2013, 34 (20), 4818-4830.
147. Huang, F.Y.; Chen, W.J.; Lee, W.Y.; Lo, S.T.; Lee, T.W.; Lo, J.M. In vitro and in vivo evaluation of lactoferrin-conjugated liposomes as a novel carrier to improve the brain delivery. Int. J. Mol. Sci., 2013, 14 (2), 2862-2874.
148. Liu, Z.; Jiang, M.; Kang, T.; Miao, D.; Gu, G.; Song, Q.; Yao, L.; Hu, Q.; Tu, Y.; Pang, Z.; Chen, H.; Jiang, X.; Gao, X.; Chen, J. Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration. Biomaterials, 2013, 34 (15), 3870-3881.
149. Xin, H.; Sha, X.; Jiang, X.; Zhang, W.; Chen, L.; Fang, X. Antiglioblastoma efficacy and safety of paclitaxel-loading Angiopepconjugated dual targeting PEG-PCL nanoparticles. Biomaterials, 2012, 33 (32), 8167-8176.
150. Ren, J.; Shen, S.; Wang, D.; Xi, Z.; Guo, L.; Pang, Z.; Qian, Y.; Sun, X.; Jiang, X. The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials, 2012, 33 (11), 3324-3333.
151. Lockman, P.R.; Oyewumi, M.O.; Koziara, J.M.; Roder, K.E.; Mumper, R.J.; Allen, D.D. Brain uptake of thiamine-coated nanoparticles. J. Control. Release, 2003, 93 (3), 271-282.
152. Bao, H.; Jin, X.; Li, L.; Lv, F.; Liu, T. OX26 modified hyperbranched polyglycerol-conjugated poly (lactic-co-glycolic acid) nanoparticles: synthesis, characterization and evaluation of its brain delivery ability. J. Mater. Sci. Mater. Med. 2012, 23 (8), 1891-1901.
153. Gosk, S.; Vermehren, C.; Storm, G.; Moos, T. Targeting antitransferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. J. Cereb. Blood Flow. Metab., 2004, 24 (11), 1193-1204.
154. Salvati, E.; Re, F.; Sesana, S.; Cambianica, I.; Sancini, G.; Masserini, M.; Gregori, M. Liposomes functionalized to overcome the blood-brain barrier and to target amyloid-β peptide: the chemical design affects the permeability across an in vitro model. Int. J. Nanomedicine, 2013, 8, 1749-1758.
155. Eavarone, D.A.; Yu, X.; Bellamkonda, R.V. Targeted drug delivery to C6 glioma by transferrin-coupled liposomes. J. Biomed. Mater. Res., 2000, 51 (1), 10-14.
156. Liu, Z.; Gao, X.; Kang, T.; Jiang, M.; Miao, D.; Gu, G.; Hu, Q.; Song, Q.; Yao, L.; Tu, Y.; Chen, H.; Jiang, X.; Chen, J. B6 Peptide-Modified PEG-PLA Nanoparticles for Enhanced Brain Delivery of Neuroprotective Peptide. Bioconjug. Chem., 2013, 24 (6), 997-1007.
157. Gao, J.Q.; Lv, Q.; Li, L.M.; Tang, X.J.; Li, F.Z.; Hu, Y.L.; Han, M. Glioma targeting and blood-brain barrier penetration by dualtargeting doxorubincin liposomes. Biomaterials, 2013, 34 (22), 5628-5639.
158. Lu, Y.J.; Wei, K.C.; Ma, C.C.; Yang, S.Y.; Chen, J.P. Dual targeted delivery of doxorubicin to cancer cells using folate conjugated magnetic multi-walled carbon nanotubes. Colloids Surf. B. Biointerfaces, 2012, 89, 1-9.
159. Al-Jamal, K.T.; Gherardini, L.; Bardi, G.; Nunes, A.; Guo, C.; Bussy, C.; Herrero, M.A.; Bianco, A.; Prato, M.; Kostarelos, K.; Pizzorusso, T. Functional motor recovery from brain ischemic insult by carbon nanotube-mediated siRNA silencing. Proc. Natl. Acad. Sci. USA, 2011, 108 (27), 10952-10957.
160. Lee, H.J.; Park, J.; Yoon, O.J.; Kim, H.W.; Lee, Y.; Kim, H.; Lee, W.B.; Lee, N.E.; Bonventre, J.V.; Kim, S.S. Amine-modified single-walled carbon nanotubes protect neurons from injury in a rat stroke model. Nat. Nanotechnol., 2011, 6 (2), 121-125.